169
Participants
Start Date
April 22, 2021
Primary Completion Date
April 12, 2023
Study Completion Date
April 12, 2023
Mepolizumab
Mepolizumab will be available as a clear to opalescent, colorless solution for SC injection in a single-use, safety syringe at a unit dose strength of 100 mg/milliliters (mL).
Placebo
Placebo will be available as a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe
Standard of care
Participants will continue to receive Standard of care as they are used to before entry in the study.
GSK Investigational Site, Beijing
GSK Investigational Site, Beijing
GSK Investigational Site, Moscow
GSK Investigational Site, Moscow
GSK Investigational Site, Yaroslavl
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Shanghai
GSK Investigational Site, Shanghai
GSK Investigational Site, Nanjing
GSK Investigational Site, Zibo
GSK Investigational Site, Yantai
GSK Investigational Site, Qingdao
GSK Investigational Site, Taiyuan
GSK Investigational Site, Xiamen
GSK Investigational Site, Wuhan
GSK Investigational Site, Wuhan
GSK Investigational Site, Guangzhou
GSK Investigational Site, Dongguan
GSK Investigational Site, Zhongshan
GSK Investigational Site, Haikou
GSK Investigational Site, Chengdu
GSK Investigational Site, Aichi
GSK Investigational Site, Aichi
GSK Investigational Site, Aichi
GSK Investigational Site, Chiba
GSK Investigational Site, Chiba
GSK Investigational Site, Fukui
GSK Investigational Site, Fukuoka
GSK Investigational Site, Fukuoka
GSK Investigational Site, Hiroshima
GSK Investigational Site, Hyōgo
GSK Investigational Site, Hyōgo
GSK Investigational Site, Ibaraki
GSK Investigational Site, Ishikawa
GSK Investigational Site, Kagawa
GSK Investigational Site, Kagoshima
GSK Investigational Site, Kanagawa
GSK Investigational Site, Kanagawa
GSK Investigational Site, Kanagawa
GSK Investigational Site, Kumamoto
GSK Investigational Site, Kyoto
GSK Investigational Site, Kyoto
GSK Investigational Site, Mie
GSK Investigational Site, Miyagi
GSK Investigational Site, Nagano
GSK Investigational Site, Niigata
GSK Investigational Site, Okayama
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
Lead Sponsor
Collaborators (1)
BioClinica, Inc.
INDUSTRY
Signant Health
OTHER
GlaxoSmithKline
INDUSTRY